Furthermore, profiling the three tumour-associated protein markers: EGFR, epithelial cell adhesion molecule (EpCAM) and HER2 on circulating EVs in a BC patient cohort, resulted in diagnosing breast tumours with high efficiency (AUC: 0.9845) (area under the receiver operating characteristic curve) and a high sensitivity of 97.37% for distinguishing malignant BC vs. healthy controls, whereas very early, stage I cases were detected with 92.31% sensitivity [166]. Here, ERBB2 is linked to breast neoplasm.